Literature DB >> 17089411

Pathogenesis of medulloblastoma and current treatment outlook.

Jaroslaw Jozwiak1, Wieslawa Grajkowska, Pawel Wlodarski.   

Abstract

Medulloblastoma is the most common malignant tumor of the cerebellum in children, with a tendency to metastasize via CSF pathway. Survival rate varies depending on several factors, but is rather favorable, with radiotherapy as the treatment of choice. Irradiation of the craniospinal axis results, however, in severe neuropsychological and psychosocial impairments pertaining to memory, attention, motor functioning, language, and visuospatial abilities. Precise mechanisms underlying the formation of medulloblastoma are still unclear, but implication of at least three signaling molecules is postulated: insulin-like growth factor-I, WNT, and Sonic hedgehog. Thanks to increasing knowledge on the cellular mechanisms contributing to tumor formation, it is possible to propose new therapies that could replace radiotherapy or allow decreasing irradiation doses. The current review presents recent developments in medulloblastoma pathophysiology research and proposed inhibitors that could constitute good candidates for further pharmacological research. Copyright 2006 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17089411     DOI: 10.1002/med.20088

Source DB:  PubMed          Journal:  Med Res Rev        ISSN: 0198-6325            Impact factor:   12.944


  12 in total

1.  High levels of PROM1 (CD133) transcript are a potential predictor of poor prognosis in medulloblastoma.

Authors:  Alessandro Raso; Samantha Mascelli; Roberto Biassoni; Paolo Nozza; Marcel Kool; Angela Pistorio; Elisabetta Ugolotti; Claudia Milanaccio; Sara Pignatelli; Manuela Ferraro; Marco Pavanello; Marcello Ravegnani; Armando Cama; Maria Luisa Garrè; Valeria Capra
Journal:  Neuro Oncol       Date:  2011-04-12       Impact factor: 12.300

Review 2.  Signaling pathway and molecular subgroups of medulloblastoma.

Authors:  Kay Ka-Wai Li; Kin-Mang Lau; Ho-Keung Ng
Journal:  Int J Clin Exp Pathol       Date:  2013-06-15

3.  Development and characterization of murine models of medulloblastoma extraneural growth in bone.

Authors:  Jessica M Grunda; Dezhi Wang; Gregory A Clines
Journal:  Clin Exp Metastasis       Date:  2013-03-15       Impact factor: 5.150

4.  Additive effects of 5-aza-2'-deoxycytidine and irradiation on clonogenic survival of human medulloblastoma cell lines.

Authors:  Ina Patties; Jutta Jahns; Guido Hildebrandt; Rolf-Dieter Kortmann; Annegret Glasow
Journal:  Strahlenther Onkol       Date:  2009-05-15       Impact factor: 3.621

5.  Radiobiologic response of medulloblastoma cell lines: involvement of beta-catenin?

Authors:  Roberta Salaroli; Tiziano Di Tomaso; Alice Ronchi; Claudio Ceccarelli; Silvia Cammelli; Alessandra Cappellini; Giuseppe Nicola Martinelli; Enza Barbieri; Felice Giangaspero; Giovanna Cenacchi
Journal:  J Neurooncol       Date:  2008-08-08       Impact factor: 4.130

6.  mTOR pathway as a potential target in a subset of human medulloblastoma.

Authors:  Tímea Pócza; Anna Sebestyén; Eszter Turányi; Tibor Krenács; Agnes Márk; Tamás Béla Sticz; Zsuzsanna Jakab; Péter Hauser
Journal:  Pathol Oncol Res       Date:  2014-04-16       Impact factor: 3.201

Review 7.  [Pediatric brain tumors].

Authors:  W Reith; S Bodea; R Mühl-Benninghaus
Journal:  Radiologe       Date:  2017-09       Impact factor: 0.635

8.  Vincristine and lomustine induce apoptosis and p21(WAF1) up-regulation in medulloblastoma and normal human epithelial and fibroblast cells.

Authors:  Zakia Shinwari; Pulicat S Manogaran; Salman A Alrokayan; Khaled A Al-Hussein; Abdelilah Aboussekhra
Journal:  J Neurooncol       Date:  2007-12-06       Impact factor: 4.130

Review 9.  Learning from Jekyll to control Hyde: Hedgehog signaling in development and cancer.

Authors:  Monique T Barakat; Eric W Humke; Matthew P Scott
Journal:  Trends Mol Med       Date:  2010-06-16       Impact factor: 11.951

10.  Medulloblastoma: molecular pathways and histopathological classification.

Authors:  Anna Borowska; Jarosław Jóźwiak
Journal:  Arch Med Sci       Date:  2016-05-18       Impact factor: 3.318

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.